| Title |
Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis
|
|---|---|
| Published in |
European Child & Adolescent Psychiatry, February 2018
|
| DOI | 10.1007/s00787-018-1125-0 |
| Pubmed ID | |
| Authors |
Sarah C. O. S. Padilha, Suzane Virtuoso, Fernanda S. Tonin, Helena H. L. Borba, Roberto Pontarolo |
| Abstract |
The aim of this study is to gather evidence of head-to-head double-blind randomized-controlled trials on the efficacy and safety of available treatments for attention deficit hyperactivity disorder (ADHD) in children and adolescents. A systematic review was conducted by two independent reviewers in ten electronic databases (PROSPERO register CRD42016043239). Methodological quality of included studies was evaluated according to the Jadad scale. Network meta-analyses were performed including double-blinded head-to-head trials comparing active allopathic drugs in patients (0-18 years old) diagnosed with ADHD. The results of efficacy and safety of atomoxetine (ATX), bupropion, buspirone (BSP), dexamphetamine, edivoxetine (EDX), guanfacine (GXR), lisdexamfetamine (LDX), methylphenidate (MPH), mixed amphetamine salts, modafinil, pindolol (PDL), reboxetine (RBX), selegiline, and venlafaxine were analyzed using ADDIS software v.1.16.5. Forty-eight trials were identified (n = 4169 participants), of which 12 were used for efficacy analysis and 33 for safety analysis. On the CGI-I scale, the analysis revealed that MPH was more effective than ATX and GXR. For the safety outcomes, according to drug ranks, LDX was more likely to cause sleep disorders (39%) as well as loss of appetite (65%) and behavior problems such as irritability (60%). BSP (71%) and EDX (44%) caused less appetite decrease. For behavioral effects, PDL was considered safest (50%). For any adverse events, RBX (89%) was the safest alternative. The lack of head-to-head trials properly reporting outcomes of interest limited some comparisons. Network meta-analysis offered a broader overview on the available treatments for ADHD, especially for safety issues, and contributes towards evidence gathering and clinical practice decisions. A core outcome set for ADHD should be designed to guide the conduction and report of clinical trials. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 11% |
| Egypt | 1 | 11% |
| Japan | 1 | 11% |
| Unknown | 6 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 159 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 24 | 15% |
| Researcher | 19 | 12% |
| Student > Master | 19 | 12% |
| Other | 13 | 8% |
| Student > Ph. D. Student | 13 | 8% |
| Other | 24 | 15% |
| Unknown | 47 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 18% |
| Psychology | 23 | 14% |
| Neuroscience | 11 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
| Social Sciences | 7 | 4% |
| Other | 29 | 18% |
| Unknown | 52 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2024.
All research outputs
#2,392,523
of 23,924,386 outputs
Outputs from European Child & Adolescent Psychiatry
#275
of 1,737 outputs
Outputs of similar age
#51,956
of 333,655 outputs
Outputs of similar age from European Child & Adolescent Psychiatry
#13
of 44 outputs
Altmetric has tracked 23,924,386 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,737 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.5. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.